According to the KEYNOTE-042 trial, the group of NSCLC patients treated with Pembrolizumab that showed ≥50% cells with PD-L1 expression in their primary tumour experienced a greater decrease in tumour mass compared to the group with PD-L1 positivity between 1% and 49%, which in turn also performed better than the group with less than 1% PD-L1+ cells [27,28]. Here, CD274 is linked to neoplasm.